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ABSTRACT MALT1 is involved in the activation of immune responses, as well as in
the proliferation and survival of certain cancer cells. MALT1 acts as a scaffold protein
for NF-B signaling and a cysteine protease that cleaves substrates, further promot-
ing the expression of immunoregulatory genes. Deregulated MALT1 activity has
been associated with autoimmunity and cancer, implicating MALT1 as a new thera-
peutic target. Although MALT1 deﬁciency has been shown to protect against experi-
mental autoimmune encephalomyelitis, nothing is known about the impact of
MALT1 on virus infection in the central nervous system. Here, we studied infection
with an attenuated rabies virus, Evelyn-Rotnycki-Abelseth (ERA) virus, and observed
increased susceptibility with ERA virus in MALT1/ mice. Indeed, after intranasal in-
fection with ERA virus, wild-type mice developed mild transient clinical signs with
recovery at 35 days postinoculation (dpi). Interestingly, MALT1/ mice developed
severe disease requiring euthanasia at around 17 dpi. A decreased induction of in-
ﬂammatory gene expression and cell inﬁltration and activation was observed in
MALT1/ mice at 10 dpi compared to MALT1/ infected mice. At 17 dpi, how-
ever, the level of inﬂammatory cell activation was comparable to that observed in
MALT1/ mice. Moreover, MALT1/ mice failed to produce virus-neutralizing anti-
bodies. Similar results were obtained with speciﬁc inactivation of MALT1 in T cells.
Finally, treatment of wild-type mice with mepazine, a MALT1 protease inhibitor, also
led to mortality upon ERA virus infection. These data emphasize the importance of
early inﬂammation and activation of T cells through MALT1 for controlling the viru-
lence of an attenuated rabies virus in the brain.
IMPORTANCE Rabies virus is a neurotropic virus which can infect any mammal. An-
nually, 59,000 people die from rabies. Effective therapy is lacking and hampered by
gaps in the understanding of virus pathogenicity. MALT1 is an intracellular protein
involved in innate and adaptive immunity and is an interesting therapeutic target
because MALT1-deregulated activity has been associated with autoimmunity and
cancers. The role of MALT1 in viral infection is, however, largely unknown. Here, we
study the impact of MALT1 on virus infection in the brain, using the attenuated ERA
rabies virus in different models of MALT1-deﬁcient mice. We reveal the importance
of MALT1-mediated inﬂammation and T cell activation to control ERA virus, provid-
ing new insights in the biology of MALT1 and rabies virus infection.
KEYWORDS ERA, MALT1, immunity, neuroinﬂammation, rabies virus
Received 27 November 2017 Accepted 15
January 2018
Accepted manuscript posted online 24
January 2018
Citation Kip E, Staal J, Verstrepen L, Tima HG,
Terryn S, Romano M, Lemeire K, Suin V,
Hamouda A, Kalai M, Beyaert R, Van Gucht S.
2018. MALT1 controls attenuated rabies virus
by inducing early inﬂammation and T cell
activation in the brain. J Virol 92:e02029-17.
https://doi.org/10.1128/JVI.02029-17.
Editor Rebecca Ellis Dutch, University of
Kentucky College of Medicine
Copyright © 2018 Kip et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to R. Beyaert,
rudi.beyaert@irc.vib-ugent.be, or S. Van Gucht,
steven.vangucht@wiv-isp.be.
* Present address: M. Kalai, Clinical Laboratory
Sciences, Clinical Evidence Generation, GSK
Vaccines, Rixensart, Belgium.
R.B. and S.V.G. contributed equally to this
article.
PATHOGENESIS AND IMMUNITY
crossm
April 2018 Volume 92 Issue 8 e02029-17 jvi.asm.org 1Journal of Virology
 o
n
 April 12, 2018 by Universiteitsbibliotheek G
ent
http://jvi.asm.org/
D
ow
nloaded from
 
The paracaspase MALT1 (mucosa-associated lymphoid tissue lymphoma transloca-tion gene 1) is an intracellular protein that mediates nuclear factor B (NF-B) and
p38/JNK mitogen-activated protein kinase signaling in response to multiple stimuli,
including antigen receptor activation in lymphocytes, dectin-driven dendritic cell acti-
vation, and thrombin- and angiotensin-induced activation of ﬁbroblasts and endothe-
lial cells (1). In resting cells, MALT1 is constitutively associated with the caspase
recruitment domain (CARD)-containing protein BCL10 and, upon stimulation, forms a
complex with one of the CARD-containing proteins, CARD9, CARD10 (CARMA3),
CARD11 (CARMA1), or CARD14 (CARMA2), depending on the cell type and stimulus (2).
The CARD-BCL10-MALT1 (CBM) complex acts as a scaffold for other proteins, including
TRAF6, which then mediates the activation of NF-B and p38/JNK (3). In addition to its
scaffold function, MALT1 holds proteolytic activity that cleaves a limited number of
proteins at well-deﬁned sites (4). MALT1 substrates include among others, NF-B family
members (5), ubiquitin regulatory enzymes (6–8), and RNase and mRNA-destabilizing
proteins (9, 10). MALT1 proteolytic activity is not essential for NF-B or p38/JNK
activation but further ﬁne-tunes gene expression that contributes to immune cell
activation, proliferation and survival. Because of its major role in lymphocyte activation
and proliferation, targeting MALT1 proteolytic activity via small compound inhibitors
is currently of high interest for the treatment of several autoimmune diseases and
lymphoma (11–13).
Genetic mouse models have provided key insights into the biology of MALT1.
MALT1/ mice are viable, fertile, and born at the expected Mendelian ratios (14, 15).
Their total number of T cells and the distribution of CD4 and CD8 T cells in the
spleen, lymph nodes, and thymus is comparable to those of wild-type mice, but T cell
activation, proliferation, and interleukin-2 (IL-2) production are decreased, leading to a
lower number of activated T cells in the periphery (15). MALT1 is also required for the
development of regulatory T cells in the thymus (16, 17), as well as the development
of marginal-zone and B1 B cells (14, 15), but is dispensable for the development of
normal B2 B cells. MALT1/ mice present impaired IgM- and CD40-induced prolifer-
ation and lower basal serum immunoglobulin levels, with IgM and IgG3 showing the
most pronounced reduction. A limited number of patients carrying MALT1 mutations
leading to severe immunodeﬁciency have been reported (18–20), further illustrating
the key role of MALT1 in innate and adaptive immunity. Finally, knock-in mice express-
ing a so-called “protease-dead” mutant of MALT1 in which the catalytic activity is
disrupted, but which can still function as a scaffold for NF-B activation, mimic all
immune defects that are observed in full MALT1/ mice, although to a lesser extent.
Surprisingly, these mice spontaneously develop autoimmunity because of a deregu-
lated effector T cell response (reviewed in reference 1).
Although genetic studies have indicated that MALT1 deﬁciency may lead to severe
immune defects, promising results upon pharmacological targeting of MALT1 in pre-
clinical mouse models of multiple sclerosis (12) and ABC-type diffuse large B cell
lymphoma (11, 13), without obvious side effects, have stirred a lot of interest in the
therapeutic targeting of MALT1. However, a better understanding of the role of MALT1
in different tissues and under different conditions is essential. Previous studies already
shown that MALT1 deﬁciency protects against experimental autoimmune encephalitis
(EAE) (12, 16, 17), illustrating a role for MALT1 in the central nervous system (CNS). In
the present study, we focused on the impact of MALT1 deﬁciency on infection with a
neurotropic virus. More speciﬁcally, we investigated whether MALT1 deﬁciency affects
the virulence of an attenuated rabies virus.
Rabies virus is a highly neurotropic negative single-stranded RNA virus that belongs
to the genus Lyssavirus, family Rhabdoviridae (21). Rabies virus normally causes a highly
lethal infection of the brain, which escapes control from the immune system (22). The
virus still kills at least 59,000 humans each year and remains an important public health
problem (23). A small number of humans have survived clinical rabies virus infection
(24, 25), suggesting that, at least under certain conditions, the immune system can clear
rabies virus from the brain. Evelyn-Rotnycki-Abelseth (ERA) virus is a highly attenuated
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rabies virus laboratory strain that was ﬁrst described in the 1960s (26, 27). In contrast
to virulent rabies virus strains, ERA virus induces a benign nonlethal infection of the
nervous system that is associated with an efﬁcient immune response (28). The ERA
strain has therefore been used as a live vaccine for oral immunization of wildlife (29).
Since the ERA virus strain causes a nonlethal brain infection in mice and can mount
protective immunity against rabies, it allows study of the mechanisms by which the
host can control rabies virus in the brain.
The role of T cell immunity in the control of rabies virus infection has been
thoroughly documented (30–32). To study the impact of MALT1 activity on rabies virus
infection, we compared the clinical and immunological effect of ERA virus infection in
MALT1/ and MALT1/ mice, as well as conditional MALT1/ mice, lacking MALT1
in speciﬁc cell types such as T cells, neuroectodermal cells, or myeloid cells. We also
examined the effect of treatment of mice with mepazine, a phenothiazine derivative
and reversible MALT1 protease activity inhibitor (33). Our results demonstrate that
MALT1 plays an important role in the control of infection by attenuated rabies virus in
the CNS of laboratory mice by inducing neuroinﬂammation and by recruiting and
activating CD8 and CD4 T cells within the brain in the early phase of infection.
RESULTS
Attenuated ERA virus becomes virulent in MALT1/ mice. Intranasal inocula-
tion of ERA virus in wild-type C57BL/6 mice resulted in a clinically benign infection with,
as expected, complete survival (34) (Fig. 1). Minor clinical signs were observed at day
10 (rough hair coat and a slightly reduced reactivity), and the general appearance
(rough hair coat) improved rapidly by 11 days postinoculation (dpi). Nevertheless, most
mice remained slightly less reactive throughout the follow-up period (35 dpi), resulting
in a clinical score of 1. In contrast, ERA virus-inoculated MALT1/ mice presented the
ﬁrst clinical signs at around 15 dpi and developed severe disease, characterized by limb
paralysis and depression, requiring euthanasia at 17 or 18 dpi. These data indicate that
MALT1 is necessary to control infection with ERA virus. Viral loads were analyzed in total
brain by quantitative reverse transcriptase PCR (RT-qPCR) and ﬂuorescent antigen test
FIG 1 MALT1 is critical to control the pathogenicity of ERA virus. MALT1/ (n  10) and MALT1/
littermates (n 10) were infected intranasally with ERA virus. Clinical symptoms (A) and survival rates (B)
were assessed. All MALT1/ mice developed severe disease and had to be euthanized. MALT1/ mice
developed only mild symptoms. The results shown are representative of two independent experiments.
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(FAT) and in the olfactory bulbs, cerebrum, and cerebellum by RT-qPCR (Fig. 2A to D).
At 10 dpi, viral loads were similar in the brains of MALT1/ and MALT1/ mice (Fig.
2C). At 17 dpi, which corresponds with the end stage of disease in MALT1/ mice, a
signiﬁcantly higher viral load was observed in the different parts of MALT1/ mice
compared to MALT1/ mouse brains (Fig. 2D). Fluorescence staining of the viral N
protein yielded a similar signal in MALT1/ and MALT1/ brains at 10 dpi, whereas
at 17 dpi more ﬂuorescent foci were observed in MALT1/ mouse brains (Fig. 2E), in
FIG 2 Virus spread in the brains of MALT1/ and MALT1/ mice after intranasal inoculation. (A) Schematic
overview of the experiment. Mice were inoculated intranasally with ERA virus and sacriﬁced at 10, 17, and 35 dpi.
(B) Proﬁle of viral RNA load in total brain determined by RT-qPCR. (C and D) Proﬁle of viral RNA load in different
parts of the brain (**, P  0.01). (E) Immunoﬂuorescence staining for viral nucleocapsid in the brain tissue. At 10
dpi, green ﬂuorescent spots indicate the abundant spread of virus in the brain of MALT1/ and MALT1/ mice.
At 17 dpi, only small amounts of viral antigens were still visible in MALT1/ mice, whereas viral antigens were still
abundant in the brains of MALT1/ mice. These results are representative of three mice per time point and per
genotype. Scale bars, 20 m; magniﬁcation, 40.
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agreement with the results obtained by RT-qPCR. These results show that deﬁciency of
MALT1 leads to a progressive and lethal increase of ERA viral load in the brain, resulting
in severe clinical signs.
Antiviral and inﬂammatory gene expression is severely disrupted in the brain
of MALT1/mice at the presymptomatic phase of infection. To further analyze the
increased virulence of ERA virus in MALT1-deﬁcient mice, the virus-induced expression
of several immune response genes in the brain was assessed. The mRNA levels of
interferons (beta interferon [IFN-] and IFN-), proinﬂammatory cytokines (tumor ne-
crosis factor [TNF], interleukin-1 [IL-1], IL-12, and IL-23), chemokines (MIP2, MCP1,
and CXCL10), Th1-associated genes (IFN-, t-bet), T-reg-associated genes (Foxp3),
inﬂammasome components (NLRP3, caspase-1), T cell markers (CD4 and CD8), and iNOS
enzyme were measured in the brains of MALT1/ or MALT1/ mice at different time
points after infection and compared to mRNA levels in the corresponding uninfected
controls. As shown in Fig. 3, no upregulation of IL-12 could be observed. At 10 dpi, the
expression of all other investigated genes was higher after ERA virus infection in
infected mice compared to noninfected mice. In contrast, at comparable time points,
virus-induced expression of the same genes was much less pronounced in the brains
of MALT1/ mice, with the exception of MCP1, MIP2, CD4, and IL-23, which were
expressed to a similar extent. The absence of Foxp3 expression reﬂects the known lack
of thymic regulatory T cells in MALT1/ mice (35), whereas the absence of CD8 and
IFN- indicates a defective cytotoxic T cell response. The antiviral IFN- response and
proinﬂammatory gene expression were also almost completely absent. At 17 dpi,
virus-induced gene expression was in most cases less pronounced compared to 10 dpi,
and differences between MALT1/ and MALT1/ were more gene dependent: the
expression of IFN- and Foxp3 was absent, whereas the expression of TNF and CXCL10
was signiﬁcantly higher in the brains of MALT1/ mice than in MALT1/ mice. The
latter results are in line with the high viral loads detected at 17 dpi in the brains of
MALT1/ versus MALT1/ mice (Fig. 2). Together, these results suggest that at the
early stage of infection (10 dpi), antiviral and inﬂammatory immune responses are
severely disrupted in MALT1/ mice.
MALT1 deﬁciency is associated with decreased inﬁltration and activation of
inﬂammatory and immune cells in the brain at the presymptomatic phase of
infection. To investigate whether the above-described defects in virus-induced cyto-
kine and chemokine expression in MALT1/mice were also associated with an altered
recruitment and activation of inﬂammatory cells, immunohistological analysis for dif-
ferent inﬂammatory cell markers was performed on brain sections obtained at 10
and 17 dpi from ERA virus-infected MALT1/ and MALT1/ mice compared to
phosphate-buffered saline (PBS)-inoculated control mice (Fig. 4). Microglial cells, which
are the resident macrophages of the CNS, and astrocytes, which are the most abundant
glial cell population, typically both respond to injury and infection by acquiring an
activated phenotype, deﬁned by morphological changes, migration, and proliferation
(36, 37). Staining for the microglia cell marker Iba1 revealed an increased number of
activated microglia at 10 and 17 dpi in MALT1/ mice compared to noninfected
brains. Microglial activation is demonstrated by the typically bigger cell body and
shorter and thicker branch processes. Resting microglial cells, observed mainly in
noninfected mice, were characterized by their smaller cell bodies and long and ramiﬁed
branch processes. In ERA virus-infected MALT1/ mice, the number of activated
microglia cells was less pronounced at both 10 and 17 dpi compared to MALT1/
mouse brains. Astrocyte activation was also evident in ERA virus-infected MALT1/
mice, as demonstrated by enhanced glial ﬁbrillary acidic protein (GFAP) immunoreac-
tivity. At 10 dpi, GFAP staining was observed in the white matter of the cerebellum,
whereas at 17 dpi, GFAP staining was observed in the white matter and in the outer
layer of the gray matter. In ERA virus-infected MALT1/ mice, astrocyte activation in
the outer layer of the gray matter was slightly reduced at 17 dpi.
Inﬁltration of CD3 T cells and Mac-3 macrophages was observed at 10 dpi in
ERA virus-infected MALT1/ mice. The T cell inﬁltrates persisted at 17 dpi, whereas
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FIG 3 Defective expression of antiviral and inﬂammatory genes in the brains of ERA virus-infected MALT1/ mice. Quantitative
RT-qPCR measurements of the indicated mRNA expression levels in brains of MALT1/ (n  7) and MALT1/ littermate mice (n 
7) at 10 and 17 dpi are shown. The results are represented as the fold increases compared to noninfected MALT1/ and MALT1/
littermate mice, respectively. Differences in the fold increase at the same time point were determined by two-way ANOVA and Sidak’s
multiple-comparison test, and statistical differences between MALT1/ and MALT1/ mice are denoted by asterisks. Asterisks (****,
***, **, and *) represent P values of 0.0001, 0.001, 0.01, and 0.05, respectively.
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macrophage inﬁltrates were no longer visible. T cell and macrophage inﬁltration was
much less pronounced in ERA virus-infected MALT1/mice at 10 dpi, but similar levels
of T cells were detected in ERA virus-infected MALT1/ and MALT1/mice at 17 dpi.
B220 B cells were detectable around the blood vessels and in the choroid plexus, but
not in the brain parenchyma, at 10 and 17 dpi in ERA virus-infected MALT1/ mice. In
contrast, almost no B cells were detected in ERA virus-infected MALT1/ mice, either
around blood vessels or in the choroid plexus. As expected, CD3, B220, or Mac-3
staining was not detected in PBS-inoculated control mice. For all stainings, results were
similar in cerebellum and hippocampus.
Inﬂammatory cell inﬁltration was also assessed by ﬂow cytometric analysis of brain
leukocytes at 10 dpi. As shown in Fig. 5A, strong leukocyte inﬁltration was observed in
ERA virus-infected MALT1/ mice compared to noninfected mice. A comparatively
lower number of leukocytes was detected in infected MALT1/ mice. Analysis of cell
populations revealed strong inﬁltration of microglial cells (CD45int CD11b), mono-
cytes, macrophages, and dendritic cells (MMDCs; CD45high CD11b), NK cells (CD49
CD3), NKT cells (CD49b CD3), and T cells (CD49b CD3), with a high proportion
FIG 4 Reduced inﬁltration and activation of inﬂammatory cells in the brains of MALT1/ mice at 10 dpi with ERA virus. Immuno-
histochemical analysis of CNS sections from ERA virus-infected MALT1/ and MALT1/ mice at 10 and 17 dpi. PBS-inoculated
MALT1/ mice were used as controls. Sections of the cerebellum and hippocampus are shown. Brain sections were immunostained
for Iba-1 (microglial cells), CD3 (T cells), Mac-3 (macrophages), B220 (B cells), and GFAP (astrocytes). PBS-injected mice showed
abundant inactive ramiﬁed microglial cells and astrocytes, but no B cell, macrophage, or T cell inﬁltration. At 10 dpi, ERA virus-infected
MALT1/mice showed activation of microglial and astroglial cells, inﬁltration of T lymphocytes and macrophages in the parenchyma,
and inﬁltration of B cells around the blood vessels and choroid plexus. In MALT1/ mice, T lymphocyte and macrophage inﬁltration,
as well as microglial activation, were reduced at 10 dpi. Moreover, B cells could not be observed around the blood vessels or the
choroid plexus in MALT1/ mice. At 17 dpi, pronounced microglial activation and T lymphocyte inﬁltration were observed in both
MALT1/ and MALT1/ mice. Macrophages were no longer visible. Astrogliosis increased further but was more pronounced in
MALT1/ mice than in MALT1/ mice. Scale bars represent 20 m (magniﬁcation, 20), 50 m (magniﬁcation, 10), or 100 m
(magniﬁcation, 4). Data are representative of two mice per condition.
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FIG 5 Flow cytometric analysis of immune cell activation and inﬁltration in the brains of ERA virus-infected mice. Immune cells were isolated from
the brains of naive mice and infected mice (MALT1/ and MALT1/) at 10 dpi. (A) Absolute numbers of leukocytes present in the brain were
ﬁrst determined, and the total numbers of each cell type were determined by the percentage of marker expression on the total number of
leukocytes. A signiﬁcant decrease in total leukocytes was observed in ERA virus-infected MALT1/ mice compared to ERA virus-infected
MALT1/ mice. (B) CD49b and CD3 markers were used to distinguish NK cells (CD49b CD3), NKT cells (CD49b CD3), and T cells (CD49b
CD3). CD8 and CD4 markers were also used. A signiﬁcant decrease in NK cells, NKT cells, and CD8 T cells was observed in ERA virus-infected
MALT1/ mice compared to ERA virus-infected MALT1/ mice. (C) CD45 and CD11b markers were used to distinguish T cells (CD3 CD11b
CD45high), microglial cells (CD11b CD45int), and MMDCs (monocytes, macrophages, and DCs; CD11b CD45high). CD45int cells were selected to
analyze microglial activation by using CD11b and CD86, a costimulatory molecule expressed on activated antigen-presenting cells. CD45high cells
(Continued on next page)
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of CD8 T cells and a few CD4 T cells (Fig. 5B and C) in ERA virus-infected MALT1/
mice. Analysis of costimulatory markers such as CD86 showed that microglia and
MMDCs were highly activated, which was conﬁrmed by analyzing the mean ﬂuores-
cence intensity (MFI) of the CD86 marker (Fig. 5C). In ERA virus-infected MALT1/
brains, the absolute number of total leukocytes was much lower compared to ERA
virus-infected MALT1/ brains (Fig. 5A), which is also reﬂected by lower numbers of
CD8 T cells, NK cells, NKT cells, activated MMDCs, and activated microglia. No
signiﬁcant difference was observed for CD3 CD4 T cells (Fig. 5B and C), which is in
line with equal CD4 mRNA expression in MALT1/ and MALT1/ mouse brains (Fig.
3). Furthermore, in vitro stimulation of leukocytes isolated from ERA virus-infected
MALT1/ brains with inactivated ERA virus showed that T cells express IL-17, IFN-,
and granzyme B, suggesting the recruitment of Th1, Th17, and CD8 T cells. In contrast,
leukocytes from ERA virus-infected MALT1/ mice produced signiﬁcantly less IL-17,
granzyme B, and IFN- (Fig. 6). Altogether, these data illustrate that MALT1 deﬁciency
is associated with decreased inﬁltration and activation of inﬂammatory and immune
cells in the brain upon ERA virus infection.
MALT1 deﬁciency is associated with a defective antiviral humoral immune
response. To investigate whether MALT1 deﬁciency also affects the humoral immune
response against ERA virus we measured rabies virus neutralizing antibodies (VNA) in
the serum. VNA were detected in the blood of MALT1/ infected mice at 17 dpi
(1.90  1.30 IU/ml). This time point was chosen because it is the endpoint of disease
for MALT1/ mice. Titers increased further at 35 dpi (6.53  3.12 IU/ml) (Fig. 7).
However, most MALT1/ mice failed to produce VNA (0.5 IU/ml). Low levels of VNA
(0.85 IU/ml) could be detected in two MALT1/mice at 17 dpi, but this had no impact
on infection and disease outcome.
To further assess the role of antibodies in the protection against ERA virus in the
brain, we tested whether the transfer of serum from immunized MALT1/ mice could
infer protection in MALT1/ mice. Pooled immune serum (4.8 IU/ml, 0.5 ml/mouse
intraperitoneally [i.p.]) was transferred to ERA virus-infected MALT1/ mice at 10 dpi,
which corresponds to the time point when MALT1/ mice normally start to produce
VNA after infection with ERA virus (Fig. 8A). Transfer of immune serum was unable to
rescue the MALT1/ mice from lethal infection (Fig. 8B). These results suggest that
antibodies alone are not sufﬁcient to confer protection and that cell-mediated immu-
nity is also necessary.
MALT1 deﬁciency in T cells is sufﬁcient to render ERA virus neurovirulent.
MALT1/ mice were previously shown to have a normal number of T cells, but their
capacity to be activated is impaired (15). We therefore hypothesized that MALT1 in T
cells might be important to control ERA virus. This was investigated by using T
cell-speciﬁc MALT1/ mice that were generated by crossing CD4-Cre mice with mice
in which the MALT1 gene is ﬂanked by two loxP Cre recombinase recognition sites
(MALT1FL/FL) (Fig. 9A). In contrast to wild-type littermates (CD4-Cre/ MALT1FL/FL),
infection of T cell-speciﬁc MALT1/ mice (CD4-Cretg/ MALT1FL/FL) with ERA virus led
to severe disease and death between 15 and 17 dpi (Fig. 9B), similarly to the phenotype
observed in MALT1 full-knockout mice (Fig. 1). In addition, we observed that most of
the T cell-speciﬁc MALT1/ mice did not mount an antibody response (Fig. 9C).
Indeed, only one mouse developed a low level of VNA (0.99 IU/ml). Accordingly, we also
observed a signiﬁcant increase of viral load in CD4-Cretg/ MALT1FL/FL compared to
their wild-type littermates (CD4-Cre/ MALT1FL/FL) (Fig. 9D). These results conﬁrm the
importance of the activation of CD4 and CD8 T cells through MALT1 to control ERA
FIG 5 Legend (Continued)
were selected to analyze monocyte, macrophage, and DC activation. Activation of microglial cells and MMDCs was determined by CD86
expression represented as the MFI. A signiﬁcant decrease of CD86 MFI was observed in ERA virus-infected MALT1/ mice compared to ERA
virus-infected MALT1/ mice, which corresponds to the dot plots. The dot plots are representative of ﬁve mice per condition. Statistical
differences between MALT1/ and MALT1/mice were determined using a Student t test . Asterisks (***, **, and *) represent P values of0.001,
0.01 and 0.05, respectively.
MALT1 Is Required To Control Attenuated Rabies Virus Journal of Virology
April 2018 Volume 92 Issue 8 e02029-17 jvi.asm.org 9
 o
n
 April 12, 2018 by Universiteitsbibliotheek G
ent
http://jvi.asm.org/
D
ow
nloaded from
 
virus in the CNS. Theoretically, impaired signaling in neurons or myeloid cells could also
be responsible for the increased pathogenicity of ERA virus in MALT1/ mice. Mice
speciﬁcally lacking MALT1 in myeloid cells (LysMCretg/ MALT1FL/FL) or cells of neu-
roectodermal origin (neurons, astrocytes, or oligodendrocytes; Nestin-Cretg/ MALT1FL/FL)
were therefore also generated and analyzed in similar infection experiments (Fig. 9A).
Infection of Nestin-Cretg/ MALT1FL/FL and LysMCretg/ MALT1FL/FL mice yielded sur-
vival results comparable to those of wild-type littermates, excluding a role for MALT1
in neurons, astrocytes, oligodendrocytes, or myeloid cells (Fig. 9B). Together, our data
demonstrate the importance of MALT1-mediated T cell activation to control infection
with a live attenuated rabies virus in the brain.
Pharmacological inhibition of MALT1 increases virulence of ERA virus.
MALT1/ mice lack both MALT1 scaffold and MALT1 catalytic activities. To better
delineate the speciﬁc role of MALT1 proteolytic activity in the control of ERA virus, we
also tested the effect of inhibition of MALT1 catalytic activity by using the small
compound inhibitor mepazine. Wild-type mice were treated daily with mepazine
starting 2 days before virus inoculation and lasting until the late stage of disease (Fig.
10A). Control mice were treated with 0.9% NaCl. Some of the mepazine-treated mice
FIG 6 Reduced granzyme B, IL-17, and IFN- production in T cells from ERA virus-infected MALT1/ mice. Immune cells were isolated from the
brains of naive mice and infected mice (MALT1/ and MALT1/) at 10 dpi and stained for the intracellular markers IFN-, IL-17, and granzyme
B. T cells were gated for their phenotypic marker CD3. (A and B) FACS analysis revealed less production of IL-17, granzyme B, and IFN- in the
T cells of ERA virus-infected MALT1/ mice compared to ERA virus-infected MALT1/ mice. The dot plots are representative of ﬁve mice per
condition. (C) A signiﬁcant decrease in T cells expressing IFN-, granzyme B, and IL-17 was observed in infected MALT1/ mice compared to
infected MALT1/ mice. Statistical differences between MALT1/ and MALT1/ mice were determined by using a Student t test. Asterisks (***,
**, and *) represent P values of 0.001, 0.01 and 0.05, respectively.
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(4/7) developed severe disease and had to be euthanized between 12 and 15 dpi, while
the remaining mice developed only mild disease and survived the infection (Fig. 10B).
At sacriﬁce, CNS viral loads of the mepazine-treated mice with severe disease were
signiﬁcantly higher than in untreated mice and reached levels similar to those observed
previously in MALT1/ mice (Fig. 10C and 2B). At 35 dpi, surviving mepazine-treated
mice and control mice presented similarly low viral loads (Fig. 10C). High levels of virus
neutralizing antibodies were detected in the blood of the surviving mepazine-treated
mice (10 IU/ml) and control mice (8.86 2.28 IU/ml), but not in the mepazine-treated
mice that developed severe disease and died (0.45  0.30 IU/ml) (Fig. 10D). These data
demonstrate that MALT1 proteolytic activity is essential for a proper immune response
and the control of rabies virus infection in the CNS.
DISCUSSION
Although attenuated vaccines are often used to immunize humans and animals,
there always remains a risk that these vaccines become pathogenic again either by
acquisition of mutations or because of increased susceptibility of the host, as has been
reported for attenuated rabies vaccines in wildlife (38–42). A better understanding of
the immunological mechanisms that control attenuated rabies virus in the CNS is
FIG 7 Defective humoral immune response in MALT1/ mice. In MALT1/ mice, antibody production
was ﬁrst detected in 1 out 7 mice at 10 dpi. At 17 dpi, neutralizing antibodies were detected in all
MALT1/ mice (n  7), and antibody levels increased further at 35 dpi (n  7). Neutralizing antibodies
were not detected in MALT1/ mice (n  7) at 10 dpi and in 5 of 7 mice at 17 dpi. The two remaining
MALT1/ mice had low levels of antibodies just above the cutoff at 17 dpi.
FIG 8 Transfer of neutralizing antibodies does not rescue MALT1/mice. (A) Schematic overview of the
experimental setup. MALT1/ mice were inoculated intranasally with the ERA virus and sacriﬁced at 35
dpi. Immune sera were collected, pooled, heat inactivated, and titrated prior to i.p. transfer to MALT1/
mice at 10 dpi (500 l, 4.8 IU/ml). (B) Survival of infected mice. All MALT1/ mice developed severe
disease and had to be euthanized, despite transfer of immune serum.
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therefore of immediate interest. Our data demonstrate an important protective role for
paracaspase MALT1-mediated signaling in the response to infection with the attenu-
ated rabies virus ERA by mediating neuroinﬂammation at the early phase of infection.
More speciﬁcally, we show that MALT1 deﬁciency in mice decreases cerebral immune
responses at the early phase of infection, as evidenced by reduced microglial, astroglial,
FIG 9 Impact of speciﬁc MALT1 deﬁciency in T cells, myeloid cells, or cells from neuroectodermal origin on ERA virus infection.
(A) Schematic overview of conditional MALT1/ mouse generation. Mice expressing the CRE recombinase gene under the
inﬂuence of the CD4, LysM, or Nestin promoter were crossed with MALT1FL/FL mice to generate conditional mice lacking MALT1
in T cells, myeloid cells, or cells from a neuroectodermal origin, respectively. Conditional mice and their wild-type littermates
were genotyped and selected for each experiment. (B) Survival of infected mice. Mice were infected intranasally with ERA virus
and monitored for disease development and survival. Mice lacking MALT1 in cells from neuroectodermal origin (Nestin-Cretg/
MALT1FL/FL) and myeloid cells (LysM-Cretg/ MALT1FL/FL) developed only mild disease, comparable to their wild-type litter-
mates. Mice lacking MALT1 in T cells (CD4-Cretg/ MALT1FL/FL) presented the same phenotype as the full MALT1/ and
developed severe disease requiring euthanasia at 15 dpi. (C) Virus neutralizing antibodies in serum. Except for one, all
CD4-Cretg/ MALT1FL/FL mice failed to mount protective levels of neutralizing antibodies. (D) Viral RNA in total brain. All T
cell-speciﬁc MALT1/mice (CD4-Cretg/ MALT1FL/FL) presented a high viral load at 15 dpi, comparable to full MALT1/mice.
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and T cell activation, less inﬁltration of macrophages and CD8 T cells, and diminished
expression of NF-B regulated proinﬂammatory mediators in the brain at 10 dpi. At a
later phase of infection (17 dpi), however, immune cell inﬁltration and activation were
comparable between MALT1/ and MALT1/mice, indicating that immune cells can
still be activated and inﬁltrate the brain in ERA virus-infected MALT1/ mice, but with
delayed kinetics compared to MALT1/mice. In agreement with the curtailed immune
response, MALT1/ mice developed severe disease, characterized by severe depres-
sion and paralysis and requiring human euthanasia, whereas MALT1/ mice devel-
oped only mild disease resolving at 11 dpi, characterized by transiently reduced
activity. Similar results were observed in conditional knockout mice lacking MALT1
speciﬁcally in T cells. In contrast, mice lacking MALT1 speciﬁcally in neuroectodermal
cells or myeloid cells survived the infection. Finally, pharmacological inhibition of
MALT1 also increased the pathogenicity of the ERA virus. Together, our results dem-
onstrate a key role for MALT1-dependent T cell activation in the control of attenuated
rabies virus.
It is important to mention that T cell-speciﬁc MALT1/ mice lack MALT1 in both
CD4 and CD8 T cells, since CD4-Cre is expressed during the double positive phase
of T cell development. CD8 T cells were the most recruited T cell population in the
brain during ERA virus infection in wild-type mice. It has been shown before that CD8
T cells are required for the early production of cytokines at the site of infection,
contribute to the clearance of rabies virus from the CNS by enhancing IFN- production
and the CNS inﬂammatory response, and kill infected cells by the release of granzyme
B (43). Consequently, viral loads were found to be higher in CD8 T cell-deﬁcient mice
(43). In MALT1/ mice, signiﬁcantly fewer CD8 T cells were recruited, whereas the
FIG 10 Treatment with mepazine in ERA virus-infected MALT1/ mice: impact on survival, viral load, and
neutralizing antibody production. (A) Schematic overview of the experimental setup. MALT1/ mice were
treated daily with mepazine (n 7) or a control solution (0.9% NaCl) (n 7) starting at day2 before virus
inoculation until the end of the experiment. Two days after the ﬁrst treatment, mice were inoculated
intranasally with ERA virus and monitored daily for signs of disease. (B) Survival curves. Four of seven
mepazine-treated mice developed severe disease and had to be euthanized. Control mice and the
remaining three mepazine-treated mice survived the infection. (C) Proﬁle of viral RNA in total brains
of mepazine-treated MALT1/ mice (n  7) and control mice (n  7) at sacriﬁce determined by RT-qPCR.
Mepazine-treated mice with severe disease had higher viral loads. (D) Humoral immune response in
mepazine-treated mice and control mice. Mepazine-treated mice with severe disease had no neutralizing
antibodies. Control mice and the three surviving mepazine-treated mice had developed protective levels
of neutralizing antibodies. The results were obtained from one experiment.
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number of CD4 T cells remained the same as in MALT1/ mice. In contrast to others
who have shown that rabies virus infection in CD8 T cell-deﬁcient mice remains
sublethal (43), we observed lethal disease in MALT1/ mice, suggesting that de-
creased activation of CD4 T cell subsets also contributes to the observed sensitization
in MALT1/ mice. In this context, ERA rabies virus infection increased expression of
the transcription factor t-bet and IFN- in the CNS, which is indicative for inﬁltration of
CD4 Th1 cells. Th1 cells were previously shown to be essential for the rapid clearance
of attenuated rabies virus from the CNS (44), and the blunted expression of t-bet and
IFN- in MALT1/ mice may thus be associated with the increased lethality. We also
found evidence for increased Th17 inﬁltration and IL-17 production in the CNS of ERA
rabies virus-infected mice. IL-17 in the brains of mice infected with a laboratory-
attenuated rabies virus has previously been reported to enhance blood-brain barrier
permeability and viral clearance (45–47). Interestingly, IL-17 levels in the brains of ERA
virus-infected MALT1/ mice were lower than in MALT1/ mice, suggesting that
MALT1 deﬁciency may decrease blood-brain barrier permeability, which on its turn may
contribute to the reduced inﬁltration of inﬂammatory cells in the brain of infected
MALT1/ mice. Loss of MALT1 has formerly been shown to also interfere with T cell
inﬁltration and expression of IL-17 in experimental autoimmune encephalitis (EAE) in
mice, a well-known model of multiple sclerosis (16, 17). In this case, MALT1 inhibition
was shown to protect against EAE by blunting T-cell mediated autoimmunity.
Effective clearance of rabies virus requires the rapid production of neutralizing
antibodies (43). ERA virus-infected MALT1/ mice failed to mount neutralizing anti-
bodies. The same was true for conditional knockout mice lacking MALT1 speciﬁcally in
T cells, illustrating that production of neutralizing antibodies against ERA virus is T cell
dependent. Although rabies virus neutralizing antibodies are important for virus clear-
ance, passive immunization of MALT1/ mice failed to rescue the mice. In situ
production of antibodies by B cells in the brain (48) or active permeabilization of the
blood-brain barrier is most likely required for antibodies to be effective against rabies
virus (49). On the other hand, cellular immunity as described above is probably also
required to control the virus in the brain. Together, these ﬁndings suggest that in the
future, besides neutralizing antibodies, markers for cellular immunity should also be
considered to assess vaccine efﬁcacy and anti-rabies immunity.
A hypothetical model for the impact of MALT1 inactivation on ERA rabies virus-
induced immune responses in the brain is depicted in Fig. 11. The high level of
cytokines and inﬂammation in wild-type mice at 10 dpi with ERA virus, which coincides
with some mild disease signs, together with the inﬁltration of activated T cells in the
brain, might be crucial for effective control of the infection. MALT1/ mice presented
less inﬁltration of activated T cells and inﬂammatory cytokine production in the brain
and a signiﬁcant reduction of CD8 T cell, NK cell, and NKT cell inﬁltration. We propose
that the reduction of immune cell inﬁltration in the brain, together with the lack of a
peripheral humoral immune response, are at the origin of the higher viral loads and
severe disease in MALT1/ mice.
The fact that MALT1 deﬁciency reduces neuroinﬂammation in the brain might also
be of interest in the context of therapeutic modulation of other neurological pathol-
ogies involving neuroinﬂammation such as Alzheimer’s disease (50), Parkinson’s disease
(51), multiple sclerosis (52), stroke (53), and neuropsychiatric diseases such as depres-
sion, schizophrenia, and autism (54, 55). In this context, the allosteric MALT1 inhibitor
mepazine has already been shown to have a therapeutic effect in EAE (12). At the same
time, however, our results indicate that MALT1 inhibitors can also increase the risk for
severe virus infection in the brain or severe adverse effects upon vaccination with
attenuated rabies viruses. Indeed, mepazine treatment of ERA virus-infected mice led to
susceptibility to virulence of ERA virus in more than half of the mice. It should be
mentioned that, similar to Nagel et al. (11), in our study mice were treated with 16 mg
mepazine/kg (body weight) every 24 h. Considering the relatively short half-life of
mepazine, a more frequent treatment schedule may still lead to stronger sensitizing
effects for ERA infection. In addition to pharmacological MALT1 inhibition, mutations in
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MALT1 leading to MALT1 deﬁciency also may sensitize an attenuated rabies virus to
neurovirulence. To date, a limited number of MALT1 deﬁcient patients have been
described (18–20), each presenting with severe combined immunodeﬁciency and being
highly susceptible to fungal, bacterial, and viral infections. Moreover, other mutations
may be less disruptive and only become apparent under certain conditions. It should
be mentioned, however, that rabies vaccination in humans uses only inactivated
vaccines. Therefore, the use of MALT1 inhibitors or MALT1 deﬁciency in combination
with rabies vaccination in humans would not impose any risks. Since it remains to be
seen whether our ﬁndings with an attenuated rabies virus also apply to other attenu-
ated viruses, it is currently premature to generalize our ﬁndings to other attenuated
virus vaccines. In future studies it will be interesting to also analyze the effect of MALT1
deﬁciency on infection with virulent rabies virus or other viruses.
MATERIALS AND METHODS
Mice. MALT1/ mice were generated and generously provided by the team of Tak Mak (15). Mice
were backcrossed for more than 10 generations into the C57BL/6 background and were intercrossed to
FIG 11 Hypothetical model of the impact of MALT1 inactivation on ERA virus-induced immune responses in the brain. In MALT1/ mice,
virus-infected neuronal cells produce CXCL10 (as shown in other studies), leading to the activation of microglia and recruitment of CXCR3-
expressing T cells and NK cells to the brain parenchyma. Activated microglia and astrocytes start to produce proinﬂammatory cytokines, iNOS and
CXCL10, which ampliﬁes the recruitment and activation of several immune cell types. Activated macrophages migrate to the cervical lymph nodes,
where they serve as antigen-presenting cells for naive T cells and trigger the differentiation to effector T cells, mainly CD4 Th1 and Th17 subsets
and cytotoxic CD8 T cells. Only activated T cells can inﬁltrate the brain. IFN--producing CD8 T cells are the main T cells recruited to the site
of infection. Th1 cells and CD8 T cells can further activate macrophages by IFN- production, and antigen-presenting cells can reactivate the
T cells that have entered the brain. CD8 T cells also produce granzyme B, mediating their cytotoxic activity and virus clearance. Th1 cells provide
help for B cell activation and immunoglobulin production outside the brain, whereas Th17 cells produce IL-17, contributing to the activation of
microglia and astrocytes, as well as enhancing blood-brain barrier permeability. The impact of MALT1 deﬁciency is represented by orange arrows.
MALT1 deﬁciency in T cells reduces their activation and differentiation by antigen-presenting cells in the periphery, resulting in less effector T cells
entering the brain. This not only results in less IFN- and IL-17 production but also lowers T cell help to activate B cells and CD8 cytotoxic T
cells, leading to defective production of virus neutralizing antibodies and reduced killing of virus-infected cells. As a consequence, viral load in
the brain increases, exacerbating disease development.
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generate MALT1/, MALT1/, and MALT1/ offspring. Mice lacking MALT1 speciﬁcally in T cells were
generated by crossing the CD4-Cre line (56) and mice in which the MALT1 gene is ﬂanked by two loxP
Cre recombinase recognition sites (MALT1FL/FL) on a C57BL/6 background. MALT1FL/FL mice were origi-
nally derived from the EUCOMM Malt1tm1a(EUCOMM)Hmgu strain. Mice lacking MALT1 speciﬁcally in cells
from neuroectoderm origin (neurons, astrocytes, and oligodendrocytes) were generated by crossing the
Nestin-Cre line (57) and MALT1FL/FL. Mice lacking MALT1 speciﬁcally in myeloid cells were generated by
crossing the LysM-Cre line (58) and MALT1FL/FL. All mice were bred and housed in ﬁlter top cages in
temperature-controlled, air-conditioned facilities with 14/10-h light/dark cycles and food and water
ad libitum and used at the age of 6 to 12 weeks. All experimental procedures were approved by the Local
Ethical Committee of the Scientiﬁc Institute of Public Health (WIV-ISP) and the Veterinary and Agro-
chemical Research Center (CODA-CERVA) (advice 070515-05).
Genotyping. MALT1/, MALT1/, and MALT1/ mice were genotyped using the primers P08_11
(GGG TAC ATC ATG GCC TGA ACA GTT G), P08_12 (TCC ACT CCA GCT CTT CTG CTA ACCAG), and P08_13
(GGG TGG GAT TAG ATA AAT GCC TGC TC), which resulted in PCR products of 900 bp for MALT1/, 1,000
bp for MALT1/, or both for heterozygous MALT1/mice. The MALT1 Flox-allele was detected with the
primers MALTcKO-F (GTT TCT CAG GTC TTT AGT TCA TGT C), CoMLT-3-R (TAT ACT CTA CAT CTC CAT GGT),
or MALTcKO-R (TTG TTT TGC AGA TCT CTG CC), which resulted in PCR products of 280 bp for MALT1/,
400 bp for MALT1FL/FL, or 345 bp for MALT1/ mice. The Cre allele was detected with the primers Cre-F
(TGC CAC GAC CAA GTG ACA GCA ATG) and Cre-R (AGA GAC GGA AAT CCA TCG CTC G), producing a
374-bp PCR fragment. Transgenic mice were identiﬁed by PCR analysis of genomic DNA extracted from
tails, and ampliﬁcation of the selected fragments was performed using the GoTaq G2 DNA polymerase
(Promega, Madison, WI) master mix according to a typical PCR program: denaturation for 5 min at 95°C;
followed by 35 to 40 cycles of 30 s at 95°C, 30 s at 55 to 60°C, and 60 s at 72°C; and then 10 min at 72°C
for ﬁnal elongation. Fragments were visualized on a 2% agarose gel.
Virus. The attenuated Evelyn-Rotnycki-Abelseth (ERA) virus, used as an oral vaccine for immunization
of wild life, was obtained from the American Type Culture Collection (reference no. VR322) (38). Viral
stocks were produced in baby hamster kidney-21 (BHK-21) cells (Deutsche Sammlung von Mikroorgan-
ismen und Zellkulturen, GmbH, Braunschweig, Germany). The lysates of infected cell cultures were
centrifuged at 20,000  g for 20 min at 4°C, and supernatants were stored at 80°C.
Virus titration. Infectious rabies virus particles were titrated by an endpoint dilution assay in BHK-21
cells. The measure of infectious virus titer was expressed as 50% tissue culture infective dose (TCID50)/ml
and represents the amount of virus per ml that gives rise to infection in 50% of inoculated tissue culture
cells. Virus titration was performed according to the Manual of Diagnostic Tests and Vaccines for
Terrestrial Animals (Ofﬁce International des Epizooties, 2008).
Virus inoculation, clinical follow-up, euthanasia, and sampling.Mice were inoculated intranasally
with ERA virus using 105 TCID50 in 25 l of PBS, during brief anesthesia with isoﬂurane, as described by
Rosseels et al. (59). Intranasal inoculation of virus was chosen since administration by this route results
in a quick invasion of the CNS. Mice were monitored once a day for signs of disease throughout the
experiment until 35 days postinoculation (dpi). A cumulative daily clinical score per mouse was obtained
by adding the scores for each parameter and ranged from 0 (no disease) to 9 (severe brain disease).
Disease signs were scored as follows: no signs  0, rough hair coat  1, depression/isolation from the
group  1, hunched back  1, slow movement  1, paresis in the front paws  1, uncoordinated
movements  1, no spontaneous movements  1, paralysis of hind legs  1, and no response to
external stimuli (end stage)  1. Disease progression is represented by a curve of the mean cumulative
score per group. Once mice reached a minimum score of 6, or at predetermined time points after virus
inoculation (10 dpi, incubation phase; 17 dpi, end stage of disease), mice were euthanized with an
overdose of ketamine (100 mg/kg; Ceva, Brussels, Belgium) and xylazine (9.9 mg/kg; Rompun 2; Bayer
Healthcare, Kiel, Germany) (300 l/mouse, i.p.). Upon terminal anesthesia, the blood was ﬂushed from the
circulatory system by transcardial perfusion with a PBS solution. Brains were collected and divided into
two halves according to a longitudinal section. One half was stored at 80°C for further analysis by
real-time RT-qPCR or FAT, and the other half was submerged in 4% formaldehyde for ﬁxation and further
immunohistochemical analysis. Serum was collected from mice at different time points postinfection and
upon euthanasia for titration of virus-neutralizing antibodies. Mice that did not develop disease signs
were terminally anesthetized, perfused, and euthanized at 35 dpi.
RNA extraction and real-time RT-qPCR assay for quantiﬁcation of viral RNA and inﬂammatory
gene expression. Seven mice per group were euthanized at each indicated time point. RNA extraction
was performed using the RNeasy minikit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. RNA concentration was calculated using Nano Vue spectrophotometry (GE Healthcare,
Bucks, UK) and 100 ng was used for reverse transcription. Reverse transcription and qPCR were
performed as described by Rosseels et al. (59). Two primers (forward and reverse) located in the
nucleoprotein N genome region were used for quantiﬁcation of viral RNA. All primer sequences are listed
in Table 1. All samples were analyzed in duplicates. Ampliﬁcation was performed on an iCycler iQ
(Bio-Rad) in a 96-well optical plate format according to the following program: 2 min at 95°C, followed
by 45 cycles of 20 s at 95°C and 30 s at 62°C. A melting-curve analysis was performed in order to verify
the speciﬁcity of amplicons. Expressions of inﬂammatory genes were normalized using the cellular 18S
rRNA housekeeping gene. Quantiﬁcation of immune gene expression was performed using the com-
parative ΔΔCT method. The fold change was calculated as 2ΔΔCT, with ΔΔCT  ΔCT sample – ΔCT ctrl.
ΔCT sample  CT gene – CT 18S and ΔCT ctrl  CT ctrl – CT 18S, with CT ctrl corresponding to the cycle threshold
(CT) of gene expression in noninfected brains. For the detection of the viral N protein’s gene, delta cycle
threshold (ΔCT) values were calculated using the following formula: ΔCT  CT ref – CT sample, with CT ref
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equal to 45, which is the maximum number of cycles of this qPCR program. A ΔCT value of 0 means there
was no detection of viral RNA.
Titration of neutralizing antibody by RFFIT. Mouse blood samples were used for measurement of
neutralizing antibodies by using the rapid ﬂuorescent focus inhibition test (RFFIT) according to the
Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Ofﬁce International des Epizooties, 2008).
Neutralizing antibody titers are expressed as international units (IU)/ml in reference to “The Second
International Standard for Anti-Rabies Immunoglobulin,” purchased from the United Kingdom National
Institute for Biological Standards and Control. Serum titers of 0.5 IU/ml or higher are an indication of
seroconversion.
Detection of nucleocapsid antigen of rabies virus by FAT. The ﬂuorescent antigen test (FAT) was
performed according to the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Brain smears
were ﬁxed with 75% acetone for 30 min at20°C and incubated with ﬂuorescein isothiocyanate-coupled
anti-nucleocapsid rabbit antibody for 30 min at 37°C.
Immunohistological analysis of mouse brains for expression of Iba-1, GFAP, B220, CD3, and
Mac-3. Virus-inoculated mice and PBS-inoculated mice were transcardially perfused with PBS. Brains
were removed, immersed in 4% paraformaldehyde, dehydrated, and embedded in parafﬁn blocks.
Sections of 2 m were obtained, and microglial cells, astrocytes, B cells, T cells, and macrophages were
detected using speciﬁc antibodies: rabbit anti-Iba-1 (Wako Chemicals, Fuggerstrasse, Germany), rabbit
anti-GFAP (Dako/Agilent Technologies, Santa Clara, CA), rat anti-B220 (eBioscience/Thermo Fisher Sci-
entiﬁc, Waltham, MA), rabbit anti-CD3 (Dako/Agilent Technologies), and rat anti-Mac-3 (BD Pharmingen,
San Diego, CA), respectively. Sections were rehydrated and incubated in 10 mM citrate buffer for 10 min
at 95°C. To remove endogenous peroxydase, tissue sections were treated with 3% H2O2 in methanol. To
block nonspeciﬁc reactions, each section was treated with 5% goat serum in antibody diluent (Dako/
Agilent Technologies) for 30 min. Primary antibody was diluted in 5% goat serum in antibody diluent
with the dilution depending on the staining realized (Iba-1, 1/1,000; CD3, 1/200; MAC-3, 1/250; B220,
1/1,000; GFAP, 1/200,000) and incubated on brain sections overnight at 4°C. Goat anti-rabbit (Dako/
Agilent Technologies) or goat anti-rat (BD Pharmingen) secondary antibodies conjugated to biotin were
diluted at 1:500 in block buffer and added for 45 min-1 h to the sections. Drops of avidin/biotin-based
peroxidase system Vectastain Elite ABC (Vector Laboratories, Burlingame, CA) were added to each section
TABLE 1 Primers used in real-time PCR
Gene Deﬁnition
Primer orientation and sequence
(5=–3=)a
RABV N Rabies virus nucleoprotein F: TGGGCATAGTTGTCACTGCTTA
R: CTCCTGCCCTGGCTCAA
IFN- Beta interferon F: GTTACACTGCCTTTGCCATCC
R: CAACAATAGTCTCATTCCACCCAG
IFN- Gamma interferon F: GGCTGTCCCTGAAAGAAAGC
R: AGCGAGTTATTTGTCATTCGG
IL-1 Interleukin-1 F: GCAACTGTTCCTGAACTCAAC
R: ATCTTTTGGGGTCCGTCAACT
TNF Tumor necrosis factor F: ACCCTCACACTCAGATCATC
R: GAGTAGACAAGGTACAACCC
IL-12p35 Interleukin-12A (p35 gene) F: CCAAGGTCAGCGTTCCAACA
R: AGAGGAGGTAGCGTGATTGACA
IL-23p19 Interleukin-23 p19 subunit F: CCGGGAGACCCAACAGATG
R: CGAAGGATCTTGGAACGGAGAAG
MIP-2 Macrophage inﬂammatory protein 2 or chemokine (C-X-C motif) ligand 2 (CXCL2) F: CCGTCATGGATGTCTACGTG
R: CAGCAGCAGGATACCACTGA
MCP-1 Monocyte chemoattractant protein 1or chemokine (C-C motif) ligand 2 (CCL2) F: AGTGTGAGGCAGAGAGCCAGCAT
R: TGGATGGAAGTCTCCTGCGTGGA
iNOS Nitric oxide synthase 2, inducible F: TGCATGGACCAGTATAAGGCAAGC
R: GCTTCTGGTCGATGTCATGAGCAA
Foxp3 Forkhead box P3 F: TTCCTTCCCAGAGTTCTTCC
R: CTCAAATTCATCTACGGTCCAC
NLRP3 NLR family pyrin domain containing 3 F: GCTCCAACCATTCTCTGACC
R: AAGTAAGGCCGGAATTCACC
Caspase-1 Caspase-1/Interleukin 1 converting enzyme (ICE) F: TATGGACAAGGCACGGGACCTATG
R: CCAGCAGCAACTTCATTTCTCTG
CXCL10 Chemokine (C-X-C motif) 10 or gamma interferon-induced protein 10 (IP-10) F: TTCTGCCTCATCCTGCTG
R: AGACATCTCTGCTCATCATTC
t-bet T-box transcription factor TBX21 F: AGAACGCAGAGATCACTCAG
R: GGATACTGGTTGGATAGAAGAGG
CD4 Cluster of differentiation 4 F: TTAATTAGAGGAGGTTCGCC
R: ACACTCGACCTCTTGTCC
CD8 Cluster of differentiation 8 F: GTATCATGAATGTGAAGCCA
R: CTGACACCAACTACAGGAAG
aF, forward; R, reverse.
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for 30 min. Finally, antibody was visualized using 3,3=-diaminobenzidine (DAB; Dako/Agilent Technolo-
gies) until speciﬁc staining appeared; slides were counterstained with hematoxylin, dehydrated, and
mounted with a xylene-based mounting medium. Sections without primary antibody were taken as
controls.
Immunophenotyping of leukocytes. Immune cells were extracted from the brain at 10 dpi as
described previously (60). In brief, brains were collected, and single-cell suspensions were prepared by
gently pressing the organs in Hanks balanced salt solution (HBSS) through a nylon mesh (mesh pore size,
100 m). After centrifugation, the cells were placed in collagenase-DNase for 1 h. After washing, the
suspension was centrifuged in 25% Percoll (Sigma-Aldrich, St. Louis, MO), the myelin layer was removed,
and the cells were suspended in HBSS containing 10% fetal calf serum (FCS). Red blood cell lysis buffer
was added to the cell pellet to eliminate erythrocytes. Cells were washed twice with ﬂuorescence-
activated cell sorting (FACS) buffer (PBS containing 10% FCS and 0.1% NaN3) and incubated with FcII/III
receptor blocking anti-CD16/CD32 (clone 2.4G2; BD Biosciences, San Jose, CA) for 15 min at 4°C. The cells
were then incubated for 30 min at 4°C protected from light with viability dye (Thermo Fisher) and the
appropriate dilutions of the following antibodies: Alexa Fluor 488-anti CD11b (clone M1/70), Brilliant
Violet-421 anti-CD45 (clone 104), PE-anti-CD49b (clone DX5), APC-Cy7-anti-CD3 (clone 145-2C11), PerCP-
Cy5.5-anti-CD8 (clone 53-6.7), APC-anti-CD4 (clone GK1.5), or PE-Cy7-anti-CD86 (clone GL1). The stained
cells were washed twice in FACS buffer, ﬁxed with 4% paraformaldehyde, and analyzed in a BD
FACSVerse ﬂow cytometer. Data were analyzed using BD FACSuite software. Antibodies were from BD
Pharmingen or Thermo Fisher.
Activation of T cells. For analysis of T cell activation in the brain, collected leukocytes were cultured
in the presence of 1 g/ml anti-CD28 (clone 37.51), 1 g/ml anti-CD49d (clone 9C10 [MFR4.B]), 10 g/ml
ERA inactivated antigens, and brefeldin A (Thermo Fisher) for 5 h at 37°C. The cells were then harvested,
washed twice, and suspended in FACS buffer containing FcII/III receptor blocking anti-CD16/CD32
(clone 2.4G2) for 15 min at 4°C. The cells were stained with viability dye and a cocktail of extracellular
antibodies (Brilliant Violet-421 anti-CD45 [clone 104], APC-Cy7-anti-CD3 [clone 145-2C11], APC-anti-CD4
[clone GK1.5], and PerCP-Cy5.5-anti-CD8 [clone 53-6.7]). The cells were then washed twice with FACS
buffer and permeabilized using Cytoﬁx/Cytoperm kit (BD Pharmingen). Cells were subsequently sus-
pended in 1 PermWash buffer (BD Pharmingen) containing a cocktail of PE-anti-IFN- (clone XMG1.2),
Alexa Fluor 488-anti-IL-17A (clone TC11-18H10), and PE-Cy7-GranzymeB (NGZB). Isotype control and
Fluorescence Minus One (FMO) control staining were performed in parallel. Cells were then washed twice
and ﬁxed with 4% paraformaldehyde. Samples were examined using a BD FACSVerse ﬂow cytometer and
analyzed with BD FACSuite software. The antibodies were obtained from BD Pharmingen or Thermo
Fisher.
Serum transfer by i.p. injection. Sera were collected at 35 dpi from immune C57BL/6 mice infected
with 105 TCID50 of ERA virus/25 l. MALT1/ mice received 500 l of serum i.p. on day 10 after virus
challenge. The sera of naive mice were used as a control. Mouse sera were heat inactivated prior to
administration (30 min at 56°C).
Treatment with mepazine. Mice were randomly treated with either mepazine or 0.9% NaCl.
Mepazine (ChemBridge) was solubilized in NaCl 0.9% at a concentration of 2 mg/ml. Mice were injected
i.p. daily with 200 l (16 mg/kg) starting 2 days before ERA virus inoculation until the end of the
experiment. Mice were monitored once a day for signs of disease throughout the experiment.
Statistical analyses. Statistical analysis was performed using the Student t test for unpaired data or
the two-way analysis of variance (ANOVA), followed by a Sidak multiple-comparison test in GraphPad
Prism7. A log-rank test was used to analyze Kaplan-Meier survival curves.
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